ResearcherFirst Hospital of Lanzhou UniversityActive in the last 2 years

Kexiang Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7041-6066; OpenAlex author ID A5113852521. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

IL20RB promotes pancreatic cancer progression by activating NF- kB signalling and promoting EMT Last author DOI 10.21203/rs.3.rs-5929013/v1 ↗
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells. Co-author DOI 10.1080/21691401.2019.1652629 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wanbai Ruan · 1 shared paper, 2025 · strength 0.33
- Paper IL20RB promotes pancreatic cancer progression by activating NF- kB signalling and promoting EMT DOI 10.21203/rs.3.rs-5929013/v1 ↗
Fanghong Wang · 1 shared paper, 2020 · strength 0.15
- Paper MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells. DOI 10.1080/21691401.2019.1652629 ↗
Zhengfeng Wang · 1 shared paper, 2020 · strength 0.15
- Paper MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells. DOI 10.1080/21691401.2019.1652629 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.